Cartesian Therapeutics (RNAC) EBITDA Margin (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of EBITDA Margin data on file, last reported at 50242.31% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 50242.31%, down 4863522.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16496.52% (up 1661131.0% YoY), and the FY2025 annual result was 32564.25%, down 3236191.0% from the prior year.
• EBITDA Margin fell to 50242.31% in Q1 2026 per RNAC's latest filing, from 6383.79% in the prior quarter.
• Over five years, EBITDA Margin peaked at 6383.79% in Q4 2025 and troughed at 50242.31% in Q1 2026.
• A 5-year average of 3914.12% and a median of 177.59% in 2023 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2025 and 2026: EBITDA Margin surged 564879 bps in 2025, then tumbled 4863522 bps in 2026.
• A 5-year view of EBITDA Margin shows it stood at 34.92% in 2022, then slumped by 6254 bps to 2149.07% in 2023, then jumped by 134 bps to 735.0% in 2024, then soared by 769 bps to 6383.79% in 2025, then plunged by 887 bps to 50242.31% in 2026.
• Business Quant data shows RNAC's EBITDA Margin at 50242.31% in Q1 2026, 6383.79% in Q4 2025, and 7945.13% in Q3 2025.